Abbott Files First Humira sBLA, AstraZeneca Seeks IV Nexium; More Filings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott has kicked off its planned label expansion program for Humira with an Oct. 1 filing for an improved physical function claim in rheumatoid arthritis.